Metsera, INC 8-K filings

Pfizer Inc. has finalized its acquisition of Metsera, Inc., converting Metsera shares into cash and contingent value rights, leading to its delisting from Nasdaq.

Metsera, Inc. and Pfizer Inc. amend their merger agreement, increasing the upfront cash consideration to $65.60 per share while adjusting contingent value rights.

Metsera announced a favorable ruling from the Delaware Court of Chancery, denying Pfizer's request for a temporary restraining order in their ongoing litigation related to the proposed acquisition.

Metsera's Board of Directors has determined that Novo Nordisk's revised acquisition proposal, valued at up to $86.20 per share, constitutes a Superior Company Proposal compared to Pfizer's offer.

Metsera, Inc. issued a strong statement rejecting Pfizer's litigation as an attempt to lower its acquisition price, vowing to defend shareholder interests.

Metsera, Inc. has issued a statement disagreeing with allegations in litigation filed by Pfizer Inc., which relates to Pfizer's proposed acquisition of Metsera and an unsolicited proposal from Novo Nordisk A/S.

Metsera's Board of Directors has determined that an unsolicited acquisition proposal from Novo Nordisk A/S, valued at up to $77.75 per share, constitutes a 'Superior Company Proposal' compared to its existing merger agreement with Pfizer Inc.

Metsera, Inc. announced positive topline data from its Phase 2b VESPER-1 and VESPER-3 trials for MET-097i, an ultra-long acting GLP-1 receptor agonist, demonstrating significant weight loss and class-leading tolerability.

Pfizer Inc. announced a definitive agreement to acquire Metsera, Inc., a clinical-stage biopharmaceutical company, for an initial enterprise value of $4.9 billion in cash, plus up to $22.50 per share in contingent value rights.

Metsera, Inc. announced positive second quarter 2025 financial results and significant advancements across its pipeline of obesity and metabolic disease therapies, including class-leading Phase 1 data for MET-233i and accelerated clinical trial enrollment for MET-097i.

Metsera, Inc. announced positive topline results from its Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog for obesity, demonstrating dose-dependent weight loss and general tolerability.

Metsera, a clinical-stage biopharmaceutical company, announced its first quarter 2025 financial results and provided an update on its pipeline, highlighting progress in its obesity and metabolic disease programs.

Metsera, Inc. announces the appointment of Jon P. Stonehouse to its Board of Directors and Audit Committee, along with the appointment of Matthew Lang as Chief Legal Officer and Secretary.

Metsera, a clinical-stage biopharmaceutical company, announced its fourth quarter and full year 2024 financial results, highlighting pipeline progress and a cash runway extended into 2027 following a successful IPO.

Metsera, Inc. discloses the 2024 annual cash bonuses awarded to its named executive officers, supplementing previously reported compensation details.

Metsera Inc. updates its certificate of incorporation and bylaws to reflect its new status as a public company after its initial public offering.